vs
Side-by-side financial comparison of Foghorn Therapeutics Inc. (FHTX) and MIND CTI LTD (MNDO). Click either name above to swap in a different company.
Foghorn Therapeutics Inc. is the larger business by last-quarter revenue ($9.2M vs $4.9M, roughly 1.9× MIND CTI LTD). MIND CTI LTD runs the higher net margin — 19.4% vs -234.3%, a 253.7% gap on every dollar of revenue. Over the past eight quarters, Foghorn Therapeutics Inc.'s revenue compounded faster (35.3% CAGR vs -45.1%).
Foghorn Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing novel therapies targeting the chromatin regulatory system to treat various types of cancer and other severe diseases. It advances a diverse pipeline of targeted drug candidates, conducting internal R&D and strategic partnerships to serve global patient populations.
MIND CTI Ltd. is a global provider of billing and customer care solutions and messaging services for voice, data, video and content services. Headquartered in Yokneam, Israel; the company also has offices in the United States of America, Iaşi in Romania and in Germany.
FHTX vs MNDO — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $9.2M | $4.9M |
| Net Profit | $-21.7M | $950.0K |
| Gross Margin | — | 55.4% |
| Operating Margin | -258.2% | 16.5% |
| Net Margin | -234.3% | 19.4% |
| Revenue YoY | 223.8% | — |
| Net Profit YoY | -11.1% | — |
| EPS (diluted) | $-0.35 | $0.05 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $9.2M | $4.9M | ||
| Q3 25 | $8.2M | $16.2M | ||
| Q2 25 | $7.6M | $11.0M | ||
| Q1 25 | $6.0M | — | ||
| Q4 24 | $2.9M | $5.2M | ||
| Q3 24 | $7.8M | $16.0M | ||
| Q2 24 | $6.9M | $10.7M | ||
| Q1 24 | $5.0M | — |
| Q4 25 | $-21.7M | $950.0K | ||
| Q3 25 | $-15.8M | $3.4M | ||
| Q2 25 | $-17.9M | $2.5M | ||
| Q1 25 | $-18.8M | — | ||
| Q4 24 | $-19.5M | $1.2M | ||
| Q3 24 | $-19.1M | $3.7M | ||
| Q2 24 | $-23.0M | $2.5M | ||
| Q1 24 | $-25.0M | — |
| Q4 25 | — | 55.4% | ||
| Q3 25 | — | 48.3% | ||
| Q2 25 | — | 50.6% | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 55.6% | ||
| Q3 24 | — | 50.6% | ||
| Q2 24 | — | 50.4% | ||
| Q1 24 | — | — |
| Q4 25 | -258.2% | 16.5% | ||
| Q3 25 | -226.9% | 18.8% | ||
| Q2 25 | -279.2% | 21.0% | ||
| Q1 25 | -385.0% | — | ||
| Q4 24 | -840.5% | 25.4% | ||
| Q3 24 | -305.5% | 22.5% | ||
| Q2 24 | -386.6% | 22.2% | ||
| Q1 24 | -558.3% | — |
| Q4 25 | -234.3% | 19.4% | ||
| Q3 25 | -194.4% | 20.9% | ||
| Q2 25 | -237.3% | 22.3% | ||
| Q1 25 | -316.4% | — | ||
| Q4 24 | -682.9% | 23.8% | ||
| Q3 24 | -244.9% | 23.3% | ||
| Q2 24 | -333.6% | 23.1% | ||
| Q1 24 | -495.4% | — |
| Q4 25 | $-0.35 | $0.05 | ||
| Q3 25 | $-0.25 | $0.16 | ||
| Q2 25 | $-0.28 | $0.12 | ||
| Q1 25 | $-0.30 | — | ||
| Q4 24 | $-0.23 | $0.06 | ||
| Q3 24 | $-0.31 | $0.18 | ||
| Q2 24 | $-0.45 | $0.12 | ||
| Q1 24 | $-0.59 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $80.9M | $8.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-108.5M | $23.0M |
| Total Assets | $198.1M | $30.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $80.9M | $8.3M | ||
| Q3 25 | $89.3M | $4.5M | ||
| Q2 25 | $72.6M | $4.5M | ||
| Q1 25 | $61.0M | — | ||
| Q4 24 | $55.5M | $4.6M | ||
| Q3 24 | $57.7M | $3.0M | ||
| Q2 24 | $138.9M | $3.0M | ||
| Q1 24 | $79.3M | — |
| Q4 25 | $-108.5M | $23.0M | ||
| Q3 25 | $-89.7M | $24.3M | ||
| Q2 25 | $-76.7M | $24.3M | ||
| Q1 25 | $-61.7M | — | ||
| Q4 24 | $-45.5M | $24.3M | ||
| Q3 24 | $-28.3M | $24.5M | ||
| Q2 24 | $-14.3M | $24.5M | ||
| Q1 24 | $-97.5M | — |
| Q4 25 | $198.1M | $30.2M | ||
| Q3 25 | $205.0M | $30.7M | ||
| Q2 25 | $226.2M | $30.7M | ||
| Q1 25 | $258.7M | — | ||
| Q4 24 | $284.0M | $30.7M | ||
| Q3 24 | $308.4M | $31.6M | ||
| Q2 24 | $328.6M | $31.6M | ||
| Q1 24 | $255.0M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-22.3M | $4.0M |
| Free Cash FlowOCF − Capex | — | $4.0M |
| FCF MarginFCF / Revenue | — | 81.0% |
| Capex IntensityCapex / Revenue | 0.0% | 0.6% |
| Cash ConversionOCF / Net Profit | — | 4.20× |
| TTM Free Cash FlowTrailing 4 quarters | — | $14.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-22.3M | $4.0M | ||
| Q3 25 | $-18.9M | $3.8M | ||
| Q2 25 | $-21.0M | $2.9M | ||
| Q1 25 | $-24.0M | — | ||
| Q4 24 | $-24.5M | $4.1M | ||
| Q3 24 | $-21.0M | $3.4M | ||
| Q2 24 | $-25.5M | $2.4M | ||
| Q1 24 | $-29.3M | — |
| Q4 25 | — | $4.0M | ||
| Q3 25 | — | $3.8M | ||
| Q2 25 | $-21.0M | $2.9M | ||
| Q1 25 | $-24.0M | — | ||
| Q4 24 | $-25.0M | $4.1M | ||
| Q3 24 | $-21.3M | $3.3M | ||
| Q2 24 | $-25.6M | $2.4M | ||
| Q1 24 | $-29.4M | — |
| Q4 25 | — | 81.0% | ||
| Q3 25 | — | 23.4% | ||
| Q2 25 | -278.2% | 25.8% | ||
| Q1 25 | -403.2% | — | ||
| Q4 24 | -875.3% | 78.9% | ||
| Q3 24 | -273.0% | 20.8% | ||
| Q2 24 | -371.0% | 22.1% | ||
| Q1 24 | -583.1% | — |
| Q4 25 | 0.0% | 0.6% | ||
| Q3 25 | 0.0% | 0.0% | ||
| Q2 25 | 0.3% | 0.0% | ||
| Q1 25 | 0.5% | — | ||
| Q4 24 | 16.8% | 0.2% | ||
| Q3 24 | 4.0% | 0.3% | ||
| Q2 24 | 0.2% | 0.4% | ||
| Q1 24 | 2.0% | — |
| Q4 25 | — | 4.20× | ||
| Q3 25 | — | 1.12× | ||
| Q2 25 | — | 1.16× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 3.32× | ||
| Q3 24 | — | 0.91× | ||
| Q2 24 | — | 0.97× | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
